[1]

Holden BA, Fricke TR, Wilson DA, Jong M, Naidoo KS, et al. 2016. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology 123(5):1036−1042

doi: 10.1016/j.ophtha.2016.01.006
[2]

Haarman AEG, Enthoven CA, Tideman JWL, Tedja MS, Verhoeven VJM, et al. 2020. The complications of myopia: a review and meta-analysis. Investigative Ophthalmology and Visual Science 61(4):49

doi: 10.1167/iovs.61.4.49
[3]

Garcia-Del Valle AM, Blázquez V, Gros-Otero J, Infante M, Culebras A, et al. 2021. Efficacy and safety of a soft contact lens to control myopia progression. Clinical & Experimental Optometry 104:14−21

doi: 10.1111/cxo.13077
[4]

Yam JC, Zhang XJ, Zhang Y, Yip BHK, Tang F, et al. 2023. Effect of low-concentration atropine eyedrops vs placebo on myopia incidence in children: the LAMP2 randomized clinical trial. JAMA 329(6):472−481

doi: 10.1001/jama.2022.24162
[5]

Hiraoka T. 2022. Myopia control with orthokeratology: a review. Eye and Contact Lens 48(3):100−104

doi: 10.1097/ICL.0000000000000867
[6]

Dong J, Zhu Z, Xu H, He M. 2023. Myopia control effect of repeated low-level red-light therapy in chinese children: a randomized, double-blind, controlled clinical trial. Ophthalmology 130(2):198−204

doi: 10.1016/j.ophtha.2022.08.024
[7]

Chia A, Chua WH, Cheung YB, Wong WL, Lingham A, et al. 2012. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (atropine for the treatment of myopia 2). Ophthalmology 119(2):347−354

doi: 10.1016/j.ophtha.2011.07.031
[8]

Yam JC, Jiang YN, Tang SM, Law AKP, Chan JJ, et al. 2019. Low-concentration atropine for myopia progression (LAMP) study: a randomized, double-blinded, placebo-controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control. Ophthalmology 126:113−124

doi: 10.1016/j.ophtha.2018.05.029
[9]

Sankaridurg P, Berntsen DA, Bullimore MA, Cho P, Flitcroft I, et al. 2023. IMI 2023 Digest. Investigative Ophthalmology & Visual Science 64(6):7

doi: 10.1167/iovs.64.10.34
[10]

Hou P, Wu D, Nie Y, Wei H, Liu L, et al. 2023. Comparison of the efficacy and safety of different doses of atropine for myopic control in children: a meta-analysis. Frontiers in Pharmacology 14:1227787

doi: 10.3389/fphar.2023.1227787
[11]

Cao K, Tian L, Ma DL, Zhao SQ, Li A, et al. 2024. Daily low-level red light for spherical equivalent error and axial length in children with myopia: a randomized clinical trial. JAMA Ophthalmology 142(6):560−567

doi: 10.1001/jamaophthalmol.2024.0801
[12]

Liu H, Yang Y, Guo J, Peng J, Zhao P. 2023. Retinal damage after repeated low-level red-light laser exposure. JAMA Ophthalmology 141(7):693695

doi: 10.1001/jamaophthalmol.2023.1548
[13]

Liao X, Yu J, Fan Y, Zhang Y, Li Y, et al. 2025. Cone density changes after repeated low-level red light treatment in children with myopia. JAMA Ophthalmology 143(6):480−488

doi: 10.1001/jamaophthalmol.2025.0835
[14]

Jiang Y, Zhu Z, Tan X, Kong X, Zhong H, et al. 2022. Effect of repeated low-level red-light therapy for myopia control in children: a multicenter randomized controlled trial. Ophthalmology 129(5):509−519

doi: 10.1016/j.ophtha.2021.11.023
[15]

Pang X, Jin X, Fu A, Wang W, Zhao B, et al. 2025. Effect of repeated low-level red light versus 0.01% topical atropine on myopia progression: a randomized crossover-controlled trial. Translational Vision Science & Technology 14(4):22

doi: 10.1167/tvst.14.4.22
[16]

Chen Y, Xiong R, Chen X, Zhang J, Bulloch G, et al. 2022. Efficacy comparison of repeated low-level red light and low-dose atropine for myopia control: a randomized controlled trial. Translational Vision Science & Technology 11(10):33

doi: 10.1167/tvst.11.10.33
[17]

Zhang M, Shi Y, Wang Y, Li Y, Qin J, et al. 2025. A comparison of repeated low-level red light and low-dose atropine for myopia control: a two-year retrospective study. Photodiagnosis and Photodynamic Therapy 55:104754

doi: 10.1016/j.pdpdt.2025.104754
[18]

Pang X, Fu A, Zheng G, Wang W, Zhong M, et al. 2025. The effect of repeated low-level red light versus 0.01% atropine treatment on axial length and choroidal parameters in children with myopia. Ophthalmology and Therapy 14(8):1739−1754

doi: 10.1007/s40123-025-01169-0
[19]

Shang L, Gao S, Wang W, Chang M, Ma N, et al. 2024. Comparison of changes in retinal vascular density and thickness after using low-level red light and 0.01% atropine in premyopic children. Translational Vision Science & Technology 13(6):23

doi: 10.1167/tvst.13.6.23
[20]

Chua W, Balakrishnan V, Chan YH, Tong L, Ling Y, et al. 2006. Atropine for the treatment of childhood myopia. Ophthalmology 113(12):2285−2291

doi: 10.1016/j.ophtha.2006.05.062
[21]

Wang W, Jiang Y, Zhu Z, Zhang S, Xuan M, et al. 2023. Axial shortening in myopic children after repeated low-level red-light therapy: post hoc analysis of a randomized trial. Ophthalmology and Therapy 12(2):1223−1237

doi: 10.1007/s40123-023-00671-7
[22]

Xu Y, Cui L, Kong M, Li Q, Feng X, et al. 2024. Repeated low-level red light therapy for myopia control in high myopia children and adolescents: a randomized clinical trial. Ophthalmology 131(11):1314−1323

doi: 10.1016/j.ophtha.2024.05.023
[23]

Xiong R, Zhu Z, Jiang Y, Wang W, Zhang J, et al. 2023. Longitudinal changes and predictive value of choroidal thickness for myopia control after repeated low-level red-light therapy. Ophthalmology 130(3):286−296

doi: 10.1016/j.ophtha.2022.10.002
[24]

Yang Y, Wei L, Wang B, Zheng W. 2024. Effects of atropine on choroidal thickness in myopic children: a meta-analysis. Frontiers in Pharmacology 15:1440180

doi: 10.3389/fphar.2024.1440180
[25]

Xiang A, He H, Li A, Meng X, Luo Y, et al. 2025. Changes in choroidal thickness and blood flow in response to form deprivation-induced myopia and repeated low-level red-light therapy in guinea pigs. Ophthalmic and Physiological Optics 45:111−119

doi: 10.1111/opo.13404
[26]

Wu H, Chen W, Zhao F, Zhou Q, Reinach PS, et al. 2018. Scleral hypoxia is a target for myopia control. Proceedings of the National Academy of Sciences of the United States of America 115(30):E7091−E7100

doi: 10.1073/pnas.1721443115
[27]

Zhou X, Zhang S, Yang F, Yang Y, Huang Q, et al. 2021. Decreased choroidal blood perfusion induces myopia in guinea pigs. Investigative Ophthalmology and Visual Science 62(15):30

doi: 10.1167/iovs.62.15.30
[28]

Chichan H, Aldujaly IH, Michalakis K, Kanal L. 2025. Photobiomodulation in ocular therapy: current status and future perspectives. International Journal of Ophthalmology 18(2):351−357

doi: 10.18240/ijo.2025.02.20
[29]

Zhang P, Zhang X, Zhu H. 2023. Photobiomodulation at 660 nm promotes collagen synthesis via downregulation of HIF-1α expression without photodamage in human scleral fibroblasts in vitro in a hypoxic environment. Graefe's Archive for Clinical and Experimental Ophthalmology 261(9):2535−2545

doi: 10.1007/s00417-023-06066-5
[30]

Myhr KL, Dong CJ, McReynolds JS. 1994. Cones contribute to light-evoked, dopamine-mediated uncoupling of horizontal cells in the mudpuppy retina. Journal of Neurophysiology 72:56−62

doi: 10.1152/jn.1994.72.1.56
[31]

Gawne TJ, Samal AV, She Z. 2023. The effects of intensity, spectral purity and duty cycle on red light-induced hyperopia in tree shrews. Ophthalmic and Physiological Optics 43(6):1419−1426

doi: 10.1111/opo.13201
[32]

Smith 3rd EL, Hung LF, Arumugam B, Holden BA, Neitz M, et al. 2015. Effects of long-wavelength lighting on refractive development in infant rhesus monkeys. Investigative Ophthalmology and Visual Science 56(11):6490−6500

doi: 10.1167/iovs.15-17025
[33]

Huang L, Gao M, Ma A, Wu Y, Fei J, et al. 2025. Effects of different powers of repeated low-level red light on form-deprivation myopia inhibition in guinea pigs. Scientific Reports 16(1):1818

doi: 10.1038/s41598-025-31458-4
[34]

Liu H, Prokosch V. 2021. Energy metabolism in the inner retina in health and glaucoma. International Journal of Molecular Sciences 22(7):3689

doi: 10.3390/ijms22073689
[35]

Wu W, Su Y, Hu C, Tao H, Jiang Y, et al. 2022. Hypoxia-induced scleral HIF-2α upregulation contributes to rises in MMP-2 expression and myopia development in mice. Investigative Ophthalmology and Visual Science 63(8):2

doi: 10.1167/iovs.63.8.2
[36]

Dai J, Wang X, Han Y, Xue C, Dong X, et al. 2025. High myopia-induced optic nerve head deformation and glaucoma progression: a three-year follow-up study. Investigative Ophthalmology and Visual Science 66(13):30

doi: 10.1167/iovs.66.13.30
[37]

Burns DH, Allen PM, Edgar DF, Evans BJW. 2020. Sources of error in clinical measurement of the amplitude of accommodation. Journal of Optometry 13:3−14

doi: 10.1016/j.optom.2019.05.002
[38]

Tan M, Li B, Xu Z, Wu D, Liu J, et al. 2025. Repeated low-intensity red light therapy for childhood myopia: a retrospective cohort study. American Journal of Translational Research 17(9):6951−6959

doi: 10.62347/MWYH6856
[39]

Yue Y, Zhang N, Liu KY, Zhong YY, Wang H, et al. 2026. Safety analysis of repeated low-level red light therapy on cone mosaic and microvasculature by adaptive optics scanning laser ophthalmoscopy. Photodiagnosis and Photodynamic Therapy 59:105473

doi: 10.1016/j.pdpdt.2026.105473